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FREEDOM OF INFORMATION APPLICATIONS AS AN
“EVERGREENING” TACTIC: SECRETARY, DEPARTMENT OF HEALTH
AND AGEING v INOVA PHARMACEUTICALS (AUSTRALIA) PTY LTD
(2010) 191 FCR 573; [2010] FCA 1442
A recent decision of the Federal Court of Australia illustrates how patent-
holding pharmaceutical companies are attempting to use Australia’s Freedom
of Information Act 1982 (Cth) to force Australian safety, quality and efficacy
regulators to disclose whether generic competitors are attempting to enter the
market. In Secretary, Department of Health and Ageing v iNova Pharmaceu-
ticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA 1442 a single
judge of the Federal Court overturned a decision of the Administrative
Appeals Tribunal (AAT) that would have compelled the Australian Therapeutic
Goods Administration (TGA) to reveal whether they were in possession of an
application to register generic versions of two iNova products: imiquimod and
phentermine. In its justification to the AAT for refusing to confirm or deny the
existence of any application, the TGA argued that to reveal the existence of
such a document would prejudice the proper administration of the National
Health Act 1953 (Cth) as it could compromise the listing of a generic on the
Pharmaceutical Benefits Scheme. The AAT failed to appreciate the extent to
which this revelation to a competitor would have undercut 2004 amendments
to the Therapeutic Goods Act 1989 (Cth) that provided penalties for
evergreening tactics involving TGA notifications to drug patent-holders and
2006 amendments to the Patents Act 1990 (Cth) which protected the right of
generic manufacturers to “springboard”. The decision of the Federal Court is
one of the first to explore the use of freedom of information legislation by
patent-holders as a potential “evergreening” technique to prolong royalties by
marginalising generic competition. Because of the significant amounts of
money involved in ensuring rapid market entry of low-cost generic products,
the issue has considerable public health significance.
INTRODUCTION
The decision of the Administrative Appeals Tribunal (AAT) in iNova Pharmaceuticals (Australia) Pty
Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010] AATA 542 and the
Department’s successful appeal in Secretary, Department of Health and Ageing v iNova
Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA 1442 illustrate the complex
relationship between Australia’s pharmaceutical regulator, the Therapeutic Goods Administration
(TGA), and originator and generic sponsors. It is argued here that iNova Pharmaceuticals’ use of the
Freedom of Information Act 1982 (Cth) (Freedom of Information Act) represents a new
“pro-evergreening” tactic for patent-holders to track and take offensive actions to defend and extend
their monopoly market share by discouraging the entry of generic products.
Although the AAT appeared unaware of the problem, similar “evergreening” strategies are being
employed by other originator companies to delay or hinder the entry of generic medications, including
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copyright infringement proceedings to protect Product Information forms,1 deceptive and misleading
advertising to health professionals,2 and the filing of incremental method and use “evergreening”
patents.3 Early identification of a competitor’s intention to list a generic product may also provide
originator companies with an opportunity to use a variety of tactics to push out competition prior to
the TGA notification which activates the “anti-evergreening” amendments in the Therapeutic Goods
Act 1989 (Therapeutic Goods Act).4 Such actions by a patent-holder would, in effect, amount to a
unilateral interpretation of the so-called “patent status-safety linkage” provision in Art 17.10.4 of the
Australia–United States Free Trade Agreement (AUSFTA).5 Given the recognised commercial value
of knowing when a competitor, and which one, is preparing to introduce a generic product, it is useful
to explore what protection, if any, regulators are able to provide applicants.6
BACKGROUND TO THE ATT APPEAL
Several iNova’s products contain as their active ingredients either imiquimod or phentermine. These
products are marketed under the brand names Aldara and Duromine respectively. Phentermine is also
sold by iNova in Australia under the name Metermine and, while all three drugs are listed on the
Australian Register of Therapeutic Goods (ARTG), Duromine is not listed on the Pharmaceutical
Benefits Scheme (PBS). Phentamine is the active ingredient in a number of appetite suppressant drugs
and is now off-patent; however, iNova’s patent over imiquimod, which is used in the treatment of
external genital and perianal warts and solar keratosis on the face and scalp, does not expire until
2013.7 Approximately 23,000 PBS prescriptions were dispensed for imiquimod in the 2009 calendar
year, with the Commonwealth paying a subsidy of $3.3 million.8 The total expenditure9 for the PBS in
the financial year to June 2010 was $8,342.03 million.10
On 22 October 2009, iNova lodged a freedom of information request with the TGA, seeking
1 Anon, “PI Copyright Case in Court”, PharmaInFocus (10 March 2011), http://www.pharmainfocus.com.au viewed 10 March
2011.
2 Faunce TA, Vines T and Gibbons H, “New Forms of Evergreening in Australia: Misleading Advertising, Enantiomers and Data
Exclusivity: Apotex v Servier and Alphapharm v Lundbeck” in “Medical Law Reporter” (2008) 16 JLM 220.
3 Faunce TA and Lexchin J, “‘Linkage’ Pharmaceutical Evergreening in Canada and Australia” (2007) 4(1) Australian and New
Zealand Journal of Health Policy 8.
4 Section 26C of the Therapeutic Goods Act 1989 (Cth) provides for pecuniary penalties of up to $10 million against a litigant
who commences a patent infringement suit not in “good faith”. Medicines Australia and the United States Pharmaceutical
Industry have continually called for the repeal of s 26C: Medicines Australia Submission to the Expert Panel Review of the
National Innovation System (2008) pp 3, 7, http://www.medicinesaustralia.com.au/files/2010/02/MA-submission-Expert-Panel-
National-Innovation-System-Review-April-2008.pdf viewed 30 April 2011; Medicines Australia Submission to Australian
Council of Intellectual Property Review of Post-Grant Patent Enforcement Strategies (October 2009) p 3, http://
www.medicinesaustralia.com.au/files/2010/08/MA-Submission-to-ACIP-on-Post-Grant-Patent-Enforcement-Strategies.pdf
viewed 30 April 2011.
5 Australia–United States Free Trade Agreement [2005] ATS 1 opened for signature 18 May 2004, Washington, entered into
force in Australia 1 January 2005.
6 Indeed, two companies, IMS and Dun & Bradstreet, were identified as private commercial intelligence gathering agencies:
iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010] AATA
542 at [42].
7 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010] AATA
542 at [5].
8 Secretary, Department of Health and Ageing v iNova Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA
1442 at [32].
9 Department of Health and Ageing, Expenditure and Prescriptions Twelve Months to 30 June 2009 (December 2009),
http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs-stats-pbexp-jun09 viewed 8 March 2011.
10 Pharmaceutical Benefits Pricing Authority, Annual Report (2010) p 9.
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a copy of any correspondence received by the Therapeutic Goods Administration and/or accepting into
evaluation any Category 1 and/or Category 3 applications to register a therapeutic product containing
the active ingredient phentermine made by sponsors other than iNova Pharmaceuticals in 2008-2009.11
On the same date, iNova also sought the same information in relation to any therapeutics
containing imiquimod. During the hearing in the AAT it emerged that iNova had been making similar
requests for information on products containing imiquimod since April 2009. Prior requests for
information were refused on the grounds – set out in s 24 of the Freedom of Information Act – that the
relevant documents could not be found or did not exist.12
On 17 November 2009, however, the Department refused to release the requested information
without confirming or denying the existence of any such documents. Following an internal review,
preliminary appeal to the AAT and remittal back to the Department, a new decision to refuse access to
the document and refusal to confirm or deny their existence was made by Dr Ruth Lopert, the
Principal Medical Adviser in the TGA and delegate to the Secretary for the relevant freedom of
information decisions.13 Dr Lopert played a central role in Australia’s negotiations of the “patent
status-safety linkage” provisions of the AUSFTA and, as a Harkness Fellow, has significant expertise
in the “evergreening” phenomenon in the United States and Canada.
A key dispute before the AAT was the question of whether the TGA could rely on ss 26 and 25 of
the Freedom of Information Act to refuse to disclose the existence (or non-existence) of any
application for the listing of a generic product on the ARTG generally. An additional, and perhaps
more interesting, submission put by the TGA to the AAT and Federal Court of Australia was that the
TGA had a responsibility to ensure the proper administration of the PBS. Therefore, the TGA was
entitled to refuse to confirm or deny the existence of a document relating to a possible application for
listing a generic product on the ARTG on the grounds set out in s 37(1)(a) of the Freedom of
Information Act.
Before discussing the specific arguments put forward by both parties, it is necessary to provide a
brief overview of the Freedom of Information Act as it applied at the time, with a focus on the rights
and obligations of iNova and the TGA.
AUSTRALIAN FREEDOM OF INFORMATION LAWS
Freedom of information laws in Australia are the responsibility of the States and Territories as well as
the Commonwealth.14 The Freedom of Information Act 1982 (Cth) applies to all Commonwealth
Departments, prescribed agencies and to federal courts and administrative tribunals when acting in an
administrative capacity.15 In 2010 the Freedom of Information Amendment (Reform) Bill (Freedom of
Information Reform Bill) was passed by Parliament,16 with the majority of its provisions coming into
force from October 2010.17 Both the original AAT appeal and Federal Court appeals were conducted
under the provisions of the pre-reform Freedom of Information Act. However, except where it is
necessary to draw attention to differences in the provisions, this analysis uses the section numbering of
the post-reform Freedom of Information Act.
11 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [7].
12 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [41].
13 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [8]-[10].
14 See eg Freedom of Information Act 1989 (ACT); Government Information (Public Access) Act 2009 (NSW); Right to
Information Act 2009 (Qld); Freedom of Information Act 1982 (Vic).
15 Freedom of Information Act 1982 (Cth), ss 4, 5, 6; however, under s 7 there are standing exceptions from the Act for security
and national defence organisations. See also Sch 2 of the Freedom of Information Act 1982 (Cth). For simplicity, information
held by these bodies will hereafter be referred to as “government information”.
16 Enacted as the Freedom of Information Amendment (Reform) Act 2010 (Cth).
17 Provisions relating to the mandatory publication of information released under freedom of information requests entered into
force on 1 May 2011. This scheme is not relevant to the cases discussed.
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Section 11 of the Freedom of Information Act grants “every person” a “legally enforceable right”
to access government information. As a rule of statutory construction, “person” includes corporate
bodies such as iNova.18 Section 11A(3) creates a mandatory obligation on the Minister or agency to
release non-exempted information, subject to the payment of any necessary fees. In most cases a
decision whether to release the documents must be made within 30 days of receipt of the request by an
agency.19 A Minister or agency may only refuse to release information if it is an exempt document for
the purposes of ss 12, 13, 14 or Pt IV of the Freedom of Information Act.
Under Pt IV of the reformed Act, exemptions are only available for:
• documents affecting national security, defence or international relations (s 33);
• Cabinet documents (s 34);
• documents affecting enforcement of law and protection of public health (s 37);20
• documents to which secrecy provisions of enactments apply (s 38);
• documents subject to legal professional privilege (s 42);
• documents containing material obtained in confidence (s 45);
• documents the disclosure of which would be contempt of Parliament or contempt of court (s 46);
• documents disclosing trade secrets or commercially valuable information (s 47); and
• the electoral rolls and related documents (s 47A).
An objective of the Freedom of Information Reform Bill was to limit the range of exempt
documents.21 To that end, the Freedom of Information Act now provides that many documents, which
had previously been exempt, are now “conditionally-exempt”. Conditionally-exempt documents must
be released if the release of the document would not be contrary to the public interest.22 At the time of
the iNova decision and appeal, however, the pre-reform Act applied and the TGA argued that, if the
documents existed, they would be exempt documents under Pt IV.23
Section 26 of the Act requires agencies to provide a notice of reasons when refusing access to a
document. The notice must:
(a) state the findings on any material questions of fact, referring to the material on which those
findings were based, and state the reasons for the decision;
(b) where the decision relates to a document of an agency, state the name and designation of the
person giving the decision; and
(c) give to the applicant appropriate information concerning:
(i) his or her rights with respect to review of the decision;
(ii) his or her rights to make a complaint to the Ombudsman in relation to the decision; and
(iii) the procedure for the exercise of the rights referred to in subparagraphs (i) and (ii); including
(where applicable) particulars of the manner in which an application for review … may be
made.
The general right to reasons provided for in s 26(1) is conditioned by s 26(2):
A notice under this section is not required to contain any matter that is of such a nature that its inclusion
in a document of an agency would cause that document to be an exempt document.
The TGA argued that, in the case of phentermine, to disclose the existence of the requested
document in a notice to iNova would result in that notice becoming an exempt document. As such, it
18 Acts Interpretation Act 1901 (Cth), s 22(1)(a).
19 Freedom of Information Act 1982 (Cth), s 15(5)(b).
20 Gaps in the sequence of sections reflect amendments to the Freedom of Information Act 1982 (Cth).
21 See eg Australian Parliament, Freedom of Information Amendment (Reform) Bill 2010, Explanatory Memorandum,
http://www.austlii.edu.au/au/legis/cth/bill_em/foiab2010381/memo_0.html viewed 9 March 2011; Faulkner J, Senator, Open
Government and Freedom of Information: Letter to Departmental Secretaries and Agency Heads (30 April 2009),
http://www.dpmc.gov.au/consultation/foi_reform/docs/letter_to_secretaries_FOI.pdf viewed 9 March 2011.
22 See Freedom of Information Act 1982 (Cth), ss 47B-47J.
23 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [11], [14].
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was open for the TGA to refuse to confirm or deny the existence of the document sought by iNova in
their notice. Furthermore, an Agency is under no obligation to provide information “as to the existence
or non-existence” of a document,
where information as to the existence or non-existence of that document, if included in a document of
an agency, would cause the last-mentioned document to be an exempt document by virtue of section 33
[documents affecting national security, defence or international relations] or 33A [documents affecting
relations with States] or subsection 37(1) [documents the disclosure of which could reasonably be
expected to … prejudice the proper administration of the law…].24
In the case of imiquimod, Dr Lopert of the TGA, relying on s 25(1) of the Freedom of
Information Act, argued that, if an application existed, it would be exempt under s 37(1) because the
information, if disclosed, “could reasonably be expected to prejudice the proper administration of the
law in a particular instance”.25 More specifically, Dr Lopert argued that the disclosure of the
information “would be used to obtain a financial advantage against the Commonwealth in the sale of
certain medicines under the PBS thereby prejudicing the administration of the National Health Act
1953”.26 Such an advantage to iNova would arise if it took steps to prevent a generic version of its
Aldara products from being placed on the PBS, where that listing would trigger a mandatory reduction
in the subsidy paid to iNova for its products.
Prior to 1 February 2011, s 99ACB of the National Health Act 1953 (Cth) imposed a 12.5%
reduction in the subsided price paid for the originator’s product once a bio-equivalent generic is listed
on the PBS. From 1 February 2011 this reduction increased to 16%.27 Delay in the introduction of a
generic would, therefore, confer a valuable commercial benefit to iNova. Not only would their
$3 million a year market be subject to less competition but their own product would not be subject to
the 12.5% (now 16%) price cut, which Dr Lopert estimated would save the community (ie cost iNova)
approximately $400,000 per year.28
Dr Lopert did not rely on s 37(1) for refusing to acknowledge the existence of a document related
to phentermine, instead relying on the exemptions contained in ss 43(1)(b) and 45(1) of the Freedom
of Information Act.29 This is understandable as iNova’s other product, Duromine, was off-patent and
was not listed on the PBS. As such, the opportunities for delaying the entry of a generic were fewer
and would not, in any event, prejudice any price reduction under s 99ACB.
PROTECTING AGAINST EVERGREENING: THE TGA’S ARGUMENTS TO THE AAT
At the centre of the TGA’s arguments were two concerns. First, due to the small generic sector in
Australia, any confirmation of the existence of an application to list a generic product on the ARTG is
likely to lead to the identification of the applicant.30 iNova’s counsel disputed the ease with which
iNova could have identified the applicant, highlighting that although there are only five members of
the Generic Medicines Association, not all generic manufacturers belong to this organisation and, in
24 Freedom of Information Act 1982 (Cth), s 25(1). This provision was unchanged by the Freedom of Information Reform Bill.
See iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [26].
25 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [15] referencing s 37(1) of the Freedom of Information Act 1982 (Cth).
26 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [15].
27 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [39].
28 Secretary, Department of Health and Ageing v iNova Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA
1442 at [32].
29 Documents relating to business affairs and documents containing material obtained in confidence, respectively.
30 Secretary, Department of Health and Ageing v iNova Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA
1442 at [46].
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any event, many originator companies also sell generic medicines.31 While this may be true, it does
not mitigate the second concern of the TGA: that, once identified, iNova could take adverse steps
against the applicant to delay the entry of the generic product and thus prejudice the administration of
the National Health Act.
Defending the refusal to confirm or deny the existence of the documents, Dr Lopert referred to the
case of Wyeth v Department of Health and Ageing (2009) 255 ALR 352; [2009] FCA 313 where the
company (Wyeth) had lodged a freedom of information application with the TGA seeking information
whether the TGA had received any applications for products containing the active ingredient
venlafaxine, over which it owned a patent (at [2], [3]). When the TGA confirmed the existence of such
applications (but not the identity of the companies), Wyeth filed for preliminary discovery as a
preliminary step to seeking injunctive relief against the applicants (at [4]). Although that motion was
denied, it undermines iNova’s claim “not to be aware of how iNova could delay an application for
listing by the TGA once accepted”.32
Dr Lopert also referred to other strategies that could be used to delay the entry of a generic
product onto the market, including:
taking injunctive action against regulators, changing the originator product to make the demonstration
of bio-equivalence more difficult (for example, developing a long acting preparation to avoid
bioequivalence), entering into covert arrangements with generics companies and offering inducements
to delay market entry, and registering and marketing one or more pseudo-generic brands.33
The AAT rejected Dr Lopert’s concerns as “entirely speculative”,34 with counsel for the appellant
suggesting Dr Lopert’s arguments “appear[ed] to be an expression of her personal opinions about
competition in the pharmaceutical industry… [and] … disapproval of reliance on the law of patents by
originator sponsors”.35 The AAT’s curt dismissal of such expert testimony about patented
pharmaceutical industry “evergreening” tactics displays a misunderstanding and/or ignorance about
the “evergreening” process in the United States, Canada and Australia.
In 2006 the Patents Act 1990 (Cth) was amended to include the new s 119A. This clarified and
extended the “springboarding” exemption that permitted generic manufacturers to submit applications
to the TGA prior to their competitor’s patent expiry in order to be ready as soon as possible after that
date to launch their cheaper but bioequivalent products. The new exemption applied to patents
claiming a pharmaceutical substance, method, use, or product and permitted springboarding at any
time during the life of a pharmaceutical patent, whether its term had been extended or not.
Although not raised by Dr Lopert, a litigation advantage may accrue to an originator company
which is able to identify a competitor early in the regulatory approval process. Anti-evergreening
provisions exist in the Therapeutic Goods Act to discourage one company (usually a patent-holding
company) from preventing, delaying or discouraging the market entry of a generic prescription
medication.36 These amendments were a concession by the Howard Government to ensure the passage
of the legislation implementing AUSFTA and have been bitterly opposed by Medicines Australia and
United States Trade Representatives, despite being technically non-discriminatory under the World
31 Secretary, Department of Health and Ageing v iNova Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA
1442 at [46].
32 Secretary, Department of Health and Ageing v iNova Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA
1442 at [48].
33 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [27].
34 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [58].
35 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [59].
36 Therapeutic Goods Act 1989 (Cth), ss 26B, 26C and 26D.
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Trade Organisation (WTO) Trade-Related Intellectual Property (TRIPS) agreement as regulating a
problem (“evergreening”) that arises solely in the pharmaceutical industry.37
Importantly, a generic manufacturer seeking the registration of their product is only required to
provide a Certificate under s 26B of the Therapeutic Goods Act “once the evaluation of the safety,
efficacy and quality of the goods has been completed under section 25 of the Therapeutic Goods Act
and the decision is to register the goods”.38 As an originator company is only liable to a potential
pecuniary cost order of $10 million if the other party has filed a s 26B certificate with the TGA, this
period of assessment provides an opportunity to commence patent infringement litigation (which is
vexatious, frivolous or otherwise not done in good faith) without fear of activating the
anti-evergreening penalty provisions set out in ss 26C and 26D of the Therapeutic Goods Act.
The gist of the Department’s argument was as follows: given the role of the Minister for Health
and Ageing (acting through her delegates at the Department of Health and Ageing and the TGA) in
administering the National Health Act, any release of information which could possibly negatively
affect the PBS listing process would undermine the operation of the law. Consequently, it could rely
on the exclusions under the Freedom of Information Act to refuse to confirm or deny the existence of
the documents.
THE RELATIONSHIP BETWEEN THE TGA AND THE PBS
Under the Therapeutic Goods Act, the TGA is responsible for evaluating the quality (batch
standardisation), safety (toxicology) and efficacy (clinical effect) of therapeutic products.39 Before a
new medicine (or a new use for an existing medicine) can be manufactured, sold or advertised for sale
in Australia, the medicine’s “sponsor” must lodge an application with the TGA for inclusion of the
good on the ARTG.40 Once the TGA has listed the medicine on the ARTG, a sponsor can then apply
to have the product listed on the PBS. Over 75% of purchased prescription medicines in Australia are
listed on the PBS,41 making PBS listing a commercial imperative.
The Pharmaceutical Benefits Advisory Committee (PBAC) determines a submission for inclusion
on the PBS, with final pricing arrangements negotiated between the sponsor and the Pharmaceutical
Benefits Pricing Authority. An application for inclusion on the PBS can run in parallel with an
application for listing on the ARTG but they are usually sequential. The price of a pharmaceutical
newly added to the PBS is referenced against the lowest priced, interchangeable drug within the
relevant therapeutic group. In theory, once a pharmaceutical comes off-patent, the entry of a new
generic version will drive down the cost of the listed medicine and, consequently, its cost to the
Australian community. Recent reforms to the PBS42 and the Memorandum of Understanding43
between the Australian Government and the patented pharmaceutical manufacturers lobby group,
Medicines Australia, to lower the price of generic medicines, however, have weakened the ability of
price referencing to reduce the price of off-patent pharmaceuticals.44
37 See further Faunce and Lexchin, n 3.
38 Certification in Relation to Patents Required in Relation to Registration or Listing under Sections 25, 26 and 26A of the
Therapeutic Goods Act 1989 (TGA), http://www.tga.gov.au/international/usftacert26b.pdf viewed 30 April 2011.
39 Therapeutic Goods Act 1989 (Cth), s 4.
40 Therapeutic Goods Act 1989 (Cth), ss 19B, 19D-22 create a range of civil and criminal offences for importing, exporting,
manufacturing or supplying a therapeutic good for use in humans that is not listed on the ARTG.
41 Clarke PM and Fitzgerald EM, Expiry of Patent Protection on Statins: Effects on Pharmaceutical Expenditure in Australia
(2010) 192(11) MJA 633, http://www.mja.com.au/public/issues/192_11_070610/cla11057_fm.html viewed 30 April 2011.
42 Faunce TA, Bai J and Nguyen D, “Impact of the Australia–US Free Trade Agreement on Australian Medicines Regulation and
Prices” (2010) 7(1) Journal of Generic Medicines 18; Faunce TA and Lofgren H, “Drug Price Reforms: The New F1-F2
Bifurcation” (2007) 30(6) Australian Prescriber 138.
43 Memorandum of Understanding between the Australian Government and Medicines Australia (2010), http://
www.health.gov.au/internet/main/publishing.nsf/Content/C6EC4D1258BBFFB6CA257721000520A2/$File/MOU%20MA.pdf
viewed 30 April 2011.
44 Simoens SRA, Expiry of Patent Protection on Statins: Effects on Pharmaceutical Expenditure in Australia (2011) 194(1)
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Importantly, however, the functions and responsibilities of the TGA are set out in the Therapeutic
Goods Act, while the PBS is administered by the Department of Health and Ageing under the National
Health Act.45
FEDERAL COURT REJECTION OF THE AAT’S FINDINGS AND REASONING
Ultimately, the AAT rejected the arguments of the Department and ordered the Department to provide
iNova with a response to their freedom of information request – effectively revealing whether or not
an application to register a generic product existed. Overturning the Department’s decision in relation
to phentamine, the AAT held that, were the Department’s submission on the construction of s 26(2) of
the Freedom of Information Act correct, it would render the more limited exemption afforded by
s 25(1) “otiose”.46 The effect of this ruling, had it not been overturned, would have limited the ability
of the government to issue a “refuse to confirm or deny” response except where the putative document
satisfied the more restricted exemption provided by s 25(1).
In the matter of imiquimod, the AAT examined whether the Department had formed a reasonable
belief that the release of any information confirming or denying the existence of an application would
prejudice the proper administration of the law. While the AAT did not reject the Department’s
submission that the TGA had a role in ensuring the proper administration of the PBS, it held that the
Department had not
[established] its contention that the delay consequent upon action taken by iNova would flow through to
the listing of the medicine on the PBS, and would have an adverse effect on the Department’s ability to
obtain value for Australian taxpayers’ money.47
The AAT held that reliance on s 37(1)(a) of the Freedom of Information Act required the
decision-maker to reach a sound judgment that the release of the information “could reasonably be
expected to” prejudice the proper administration of the law.48 To satisfy this test, the AAT argued that
the decision-maker needed to establish the following five criteria:
(1) that disclosure of the existence of an application for ARTG listing of a bioequivalent generic
product would lead to iNova being able to identify the sponsor of the generic product;
(2) that iNova would take consequent action on discovering the identity of the sponsor of the generic
product;
(3) that such action by iNova would delay the ARTG listing of the generic product;
(4) that a delay in ARTG listing would result in a delay in PBS listing; and
(5) that a delay in PBS listing would delay a reduction in the subsidy provided by the government for
the originator product.49
Though the AAT accepted that a delay in ARTG listing would result in a delay in PBS listing
(point (4)) and that any delay in PBS listing “could result” in a delay in reducing the subsidy paid to
MJA 52 (Letters), http://www.mja.com.au/public/issues/194_01_030111/letters_030111_fm-7.html viewed 30 April 2011;
Clarke and Fitzgerald, n 41; Faunce TA, “Reference Pricing for Pharmaceuticals: Is the Australia–United States Free Trade
Agreement Affecting Australia’s Pharmaceutical Benefits Scheme?” (2007) 187(4) MJA 240 (eMJA rapid online publication
13 June 2007).
45 Importantly, the TGA is a division of the Department of Health and Ageing and is not a separate portfolio agency.
46 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [34]. The AAT relied on the principles of statutory interpretation set out in Anthony Hordern & Sons Ltd v
Amalgamated Clothing and Allied Trades Union of Australia (1932) 47 CLR 1 at 7 (Gavan Duffy CJ and Dixon J); R v Wallis
(1949) 78 CLR 529 at 550 (Dixon J).
47 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 (at [65]).
48 Secretary, Department of Health and Ageing v iNova Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA
1442 at [36] (emphasis added).
49 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [65]. The AAT also indicated that success on point (5) was unlikely to assist the Department as any price reduction
triggered by the listing of a generic product was “effected by operation of law rather than as a consequence of how the law is
administered in a particular instance” (at [70]). Consequently, the TGA could not argue that the release of the document would
affect the proper administration of the law.
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an originator company (point (5)),50 it found that the Department had not established the other
criteria.51 Crucially, it held that the Department had not demonstrated any capacity for iNova to
frustrate the registration of a product on the ARTG once an application had been submitted. As such,
reliance on s 37(1)(a) was unavailable to the Department and, therefore, it could not refuse to “confirm
or deny” the existence of an application under s 25(1) of the Act.
Ultimately, the practical effect of the AAT decision (had it not been successfully appealed) would
have been limited to compelling the Department to confirm the existence of an application to register
a generic product. The Department may still have been able to rely on other provisions to exempt the
actual application from release. Indeed, given that the pre-reform Freedom of Information Act included
provisions preventing the release of commercial in-confidence information, this would have been an
almost certainty. Nonetheless, if, as the Department had argued, the prejudice to the PBS would arise
from the mere disclosure of the existence of the document, there could have been significant
consequences for the generic company identified as the applicant.
On appeal in Secretary, Department of Health and Ageing v iNova Pharmaceuticals (Australia)
Pty Ltd (2010) 191 FCR 573; [2010] FCA 1442 (at [59], the Federal Court rejected the reasoning of
the AAT in relation to the ability of the Department to rely on s 26 of the Freedom of Information Act,
as well as s 25, to refuse to confirm or deny the existence of a document. Rather, the court found that
ss 25 and 26 “are directed at different questions”. In distinguishing the “work” required of both
sections, the court held (at [60]):
Section 25 of the FOI Act has work to do, notwithstanding that other provisions in the FOI Act
authorise a similar mechanism for protecting certain kinds of information. Section 25 authorises a
response that neither confirms nor denies the existence of documents, absent any search for documents
of the kind requested. A similar response under s 26(2) is authorised, after a search has been undertaken.
That response, however, is permitted only where the inclusion of information about documents would
make the notice required under s 26(1) itself an exempt document.
While the court’s decision, on its face, supported the original decision of the TGA, in practical
terms it weakened the protection afforded to an applicant under s 26(1) of the Freedom of Information
Act. As the court itself noted (at [61]):
An informed person would know that a response neither confirming nor denying the existence of a
document [pursuant to s 26 of the Freedom of Information Act] necessarily implied that there were such
documents because, on the view contended for, the agency would be bound to state that there were no
documents.
Indeed, the court went so far as to suggest a possible strategy for a patent holder to monitor the TGA
for signs of new listing activity (at [62]):
[A] person making a request under the FOI Act … could make periodic requests for the same
information in order to see whether the form of the response changed over time [ie from “no document
exists” to a refusal to “confirm or deny” the existence of a document]. According to the frequency with
which requests were made, that person could determine when a document [ie application to register a
competitor product] first existed.
Whether it is desirable for courts to offer in their judgments new, “judicially approved” models
for circumventing the spirit of a law is a question best considered by the courts themselves. In a
different IP context, the full Bench of the Federal Court has recently provided what many argue is a
“how-to” guide for content owners to effectively build a case against an internet service provider for
copyright infringement authorisation.52 While it is clear and proper that industry and other parties will
model future practice on the determinations of a court, it may be a step too far for the courts
themselves to provide a draft standard-operating procedure in their obiter.
50 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [70].
51 iNova Pharmaceuticals (Australia) Pty Ltd v Secretary, Department of Health and Ageing (2010) 116 ALD 448; [2010]
AATA 542 at [66]-[69].
52 Roadshow Films Pty Ltd v iiNet Ltd (2011) 275 ALR 1; [2011] FCAFC 23; anon, “Federal Court Rules Against Hollywood”
(24 February 2011), Lawyers Weekly (online), http://www.lawyersweekly.com.au/blogs/top_stories/archive/2011/02/24/federal-
court-rules-against-hollywood.aspx viewed 30 April 2011; AFACT, “iiNet Decision: Judges Pave the Way for ISPs to be Held
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Having found in favour of the Department’s use of s 26, it was not strictly necessary for the court
to further consider the AAT’s finding that the Department could not rely on s 37(1)(a) of the Freedom
of Information Act (at [66]). However, the court held (at [67]-[68]) that the five criteria set out by the
AAT53 were misconstrued as they placed too heavy an emphasis on iNova’s state of mind and capacity
to identify a putative applicant. Section 37(1)(a) of the Freedom of Information Act sets out an
objective test, with the decision-maker only needing to form a reasonable belief that disclosure
“would, or could reasonably be expected to, prejudice the enforcement or proper administration of the
law”. The AAT fell into error by holding that the Department had to form a belief that iNova per se
had the capacity to prejudice the proper administration of the law (at [67]). Rather, so long as it “could
reasonably be expected” that anyone could prejudice the effective administration of the law, then a
decision-maker could rely on s 37(1)(a) (at [67]). It is not clear who, other than the patentee, would
seek to prejudice the administration of the PBS and the court did not provide any examples. Thus,
while the court upheld the original decision of the TGA, it is a partial victory at best, with more
guidance provided to industry than to bureaucrats in how to “work” the Freedom of Information Act.
CONCLUSION
The TGA’s submissions to both the AAT and the Federal Court represent a bold claim to be a joint
administrator of the PBS, and presume a logical or inevitable connection between an application for
listing a therapeutic good on the ARTG and a submission to the PBAC for inclusion of that product on
the PBS. Recent decisions by the Federal Cabinet to defer consideration of PBAC recommendations to
temporarily protect the budget bottom line do not undermine this line of logic. However, while the
TGA remains part of the Department of Health and Ageing, the decision of the Federal Court in
Secretary, Department of Health and Ageing v iNova appears on its face to support the TGA’s reliance
on ss 25(1) and 26(2) of the Freedom of Information Act to protect the identity of generic
manufactures seeking to register a product containing a patented ingredient.
In practice, however, the Federal Court’s decision highlights the need for the Australian Federal
Government to create a multidisciplinary oversight body of this area similar to the Office of Patented
Medicines and Liaison operating under Health Canada. As the Federal Court explained, the present
under-regulated system permits a patented pharmaceutical freedom of information applicant to submit
multiple freedom of information requests over a period of time, “fishing” for a change in the form of
a rejection letter as a signal that an application by a potential generic competitor had been received.
The problem is a significant one and will not simply go away. Early commencement of litigation in the
registration process may also confer an additional advantage on an originator company which could
run litigation as a delaying tactic without fear of being subject to a $10 million cost order under s 26D
of the Therapeutic Goods Act.
Nonetheless, by affirming the responsibility of the TGA to properly administer the PBS, the value
of freedom of information requests by originator companies may be seen as a less effective tool to
monitor and pre-empt the entry of competitors into the market. Australia needs an “evergreening”
oversight body. Protracted desuetude is not a practical regulatory option in this instance.
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